🎉 M&A multiples are live!
Check it out!

Hisamitsu Pharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Hisamitsu Pharmaceutical and similar public comparables like Julphar, Benevolent AI, and Pharming.

Hisamitsu Pharmaceutical Overview

About Hisamitsu Pharmaceutical

Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan. The company collaborates with its subsidiaries and associates in operating its business across two segments, The Medical and Related Product segment and the Others segment. The Medical segment represents the company's foremost revenue generating operations. It markets drugs under the Salanpas, Salonsip, Lifecella, Mohrus and Keplat brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions and ointments. The Others segment refers to its miscellaneous businesses such as cable television broadcasting, internet connection, packing materials and insurance. Apart from its primary market in Japan, Hisamitsu has a reach across other regions like North America.


Founded

1944

HQ

Japan
Employees

3.4K+

Website

hisamitsu.co.jp

Financials

LTM Revenue $1.0B

LTM EBITDA n/a

EV

$1.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Hisamitsu Pharmaceutical Financials

Hisamitsu Pharmaceutical has a last 12-month revenue of $1.0B and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Hisamitsu Pharmaceutical achieved revenue of $942M and an EBITDA of $162M.

Hisamitsu Pharmaceutical expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Hisamitsu Pharmaceutical valuation multiples based on analyst estimates

Hisamitsu Pharmaceutical P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $799M $853M XXX XXX XXX
Gross Profit $466M $483M XXX XXX XXX
Gross Margin 58% 57% XXX XXX XXX
EBITDA $115M $140M XXX XXX XXX
EBITDA Margin 14% 16% XXX XXX XXX
Net Profit $64.2M $78.0M XXX XXX XXX
Net Margin 8% 9% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Hisamitsu Pharmaceutical Stock Performance

As of April 15, 2025, Hisamitsu Pharmaceutical's stock price is JPY 4400 (or $29).

Hisamitsu Pharmaceutical has current market cap of JPY 321B (or $2.1B), and EV of JPY 196B (or $1.3B).

See Hisamitsu Pharmaceutical trading valuation data

Hisamitsu Pharmaceutical Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.3B $2.1B XXX XXX XXX XXX $1.94

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Hisamitsu Pharmaceutical Valuation Multiples

As of April 15, 2025, Hisamitsu Pharmaceutical has market cap of $2.1B and EV of $1.3B.

Hisamitsu Pharmaceutical's trades at 1.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Hisamitsu Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Hisamitsu Pharmaceutical and 10K+ public comps

Hisamitsu Pharmaceutical Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.3B XXX XXX XXX
EV/Revenue 1.4x XXX XXX XXX
EV/EBITDA 8.2x XXX XXX XXX
P/E 23.6x XXX XXX XXX
P/E/Growth 1.0x XXX XXX XXX
EV/FCF 38.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Hisamitsu Pharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Hisamitsu Pharmaceutical Valuation Multiples

Hisamitsu Pharmaceutical's NTM/LTM revenue growth is 4%

Hisamitsu Pharmaceutical's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, Hisamitsu Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Hisamitsu Pharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Hisamitsu Pharmaceutical and other 10K+ public comps

Hisamitsu Pharmaceutical Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 7% XXX XXX XXX XXX
EBITDA Margin 17% XXX XXX XXX XXX
EBITDA Growth 22% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 21% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $0.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue 46% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Hisamitsu Pharmaceutical Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Hisamitsu Pharmaceutical M&A and Investment Activity

Hisamitsu Pharmaceutical acquired  XXX companies to date.

Last acquisition by Hisamitsu Pharmaceutical was  XXXXXXXX, XXXXX XXXXX XXXXXX . Hisamitsu Pharmaceutical acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Hisamitsu Pharmaceutical

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Hisamitsu Pharmaceutical

When was Hisamitsu Pharmaceutical founded? Hisamitsu Pharmaceutical was founded in 1944.
Where is Hisamitsu Pharmaceutical headquartered? Hisamitsu Pharmaceutical is headquartered in Japan.
How many employees does Hisamitsu Pharmaceutical have? As of today, Hisamitsu Pharmaceutical has 3.4K+ employees.
Who is the CEO of Hisamitsu Pharmaceutical? Hisamitsu Pharmaceutical's CEO is Mr. Kazuhide Nakatomi.
Is Hisamitsu Pharmaceutical publicy listed? Yes, Hisamitsu Pharmaceutical is a public company listed on TKS.
What is the stock symbol of Hisamitsu Pharmaceutical? Hisamitsu Pharmaceutical trades under 4530 ticker.
When did Hisamitsu Pharmaceutical go public? Hisamitsu Pharmaceutical went public in 1962.
Who are competitors of Hisamitsu Pharmaceutical? Similar companies to Hisamitsu Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Hisamitsu Pharmaceutical? Hisamitsu Pharmaceutical's current market cap is $2.1B
What is the current revenue of Hisamitsu Pharmaceutical? Hisamitsu Pharmaceutical's last 12-month revenue is $1.0B.
What is the current EV/Revenue multiple of Hisamitsu Pharmaceutical? Current revenue multiple of Hisamitsu Pharmaceutical is 1.2x.
What is the current revenue growth of Hisamitsu Pharmaceutical? Hisamitsu Pharmaceutical revenue growth between 2023 and 2024 was 7%.
Is Hisamitsu Pharmaceutical profitable? Yes, Hisamitsu Pharmaceutical is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.